Eli Lilly and Company (NYSE:LLY) Shares Purchased by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 1.8% in the 2nd quarter, Holdings Channel.com reports. The firm owned 369,922 shares of the company’s stock after buying an additional 6,621 shares during the period. Eli Lilly and Company makes up approximately 0.5% of Commonwealth Equity Services LLC’s investment portfolio, making the stock its 25th largest position. Commonwealth Equity Services LLC’s holdings in Eli Lilly and Company were worth $334,920,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Everpar Advisors LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $1,845,000. International Assets Investment Management LLC increased its stake in Eli Lilly and Company by 5.3% during the 4th quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock valued at $7,343,000 after buying an additional 632 shares during the period. AMJ Financial Wealth Management acquired a new position in Eli Lilly and Company during the 4th quarter valued at about $201,000. GUNN & Co INVESTMENT MANAGEMENT INC. raised its position in shares of Eli Lilly and Company by 124.7% during the 4th quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 1,438 shares of the company’s stock worth $838,000 after buying an additional 798 shares in the last quarter. Finally, Providence First Trust Co acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $274,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Johna Norton sold 7,056 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares in the company, valued at approximately $20,835,194.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the transaction, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The disclosure for this sale can be found here. Insiders sold 1,097,883 shares of company stock valued at $972,022,568 over the last quarter. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $19.82 on Friday, hitting $960.02. The company’s stock had a trading volume of 2,555,073 shares, compared to its average volume of 3,070,253. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The firm has a market cap of $912.41 billion, a P/E ratio of 141.39, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company has a fifty day moving average price of $892.64 and a 200-day moving average price of $821.53.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.54%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Analyst Ratings Changes

A number of research firms recently commented on LLY. Truist Financial reiterated a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. BMO Capital Markets boosted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Wells Fargo & Company raised their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Finally, Barclays upped their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Two investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $961.76.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.